Clinical trials: Refractory Focal Epilepsy
Refractory Epilepsy
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age…
- Trial name
- NCT00228969
- Testing
- RWJ-333369
- Where
- 61 sites in United States, Argentina and 6 more
- Sponsor
- SK Life Science, Inc.
Epilepsy
Pharmacokinetics, Efficacy and Tolerability of BIA 2-093
The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate in children and adolescents with epilepsy.
- Trial name
- NCT02170064
- Testing
- BIA 2-093 (Eslicarbazepine acetate)
- Where
- Romania
- Volunteers
- 35 people
- Sponsor
- Bial - Portela C S.A.
Focal Onset Seizures
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal…
- Trial name
- NCT06377930
- Testing
- RAP-219
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rapport Therapeutics Inc.
Refractory Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
This was a phase III 4-part study in multiple centres. Part I was a 26-week parallel-group, randomised, placebo-controlled period (8 weeks single-blind placebo baseline, 2 weeks double-blind titration, 12 weeks maintenance, and 4…
- Trial name
- NCT00957684
- Testing
- eslicarbazepine acetate
- Where
- Portugal
- Volunteers
- 402 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Epilepsies, Partial
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
The purpose of this study is to evaluate the effectiveness and safety of the novel compound RWJ-333369 in reducing the frequency of seizures in patients with epilepsy.
- Trial name
- NCT00210522
- Testing
- RWJ 333369
- Volunteers
- 421 people
- Sponsor
- SK Life Science, Inc.
Partial Epilepsy in Children and Adolescents
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
The purpose of this study is to examine the efficacy and safety of Eslicarbazepine acetate (BIA 2-093) when given with other anti-epileptic drugs to treat children with partial seizures whose condition has not been controlled by…
- Trial name
- NCT00988156
- Testing
- Eslicarbazepine acetate (BIA 2-093), Eslicarbazepine acetate
- Where
- 91 sites in Austria, Bosnia and Herzegovina and 19 more
- Volunteers
- 304 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures
The purpose of this study is to evaluate the efficacy and safety of topiramate as add-on therapy in epilepsy patients with difficult to treat, partial-onset seizures who are taking one or two standard anti-epileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236860
- Testing
- topiramate
- Volunteers
- 56 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Partial Epilepsy
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy…
- Trial name
- NCT00957047
- Testing
- eslicarbazepine acetate, ESL - Part II
- Where
- Portugal
- Volunteers
- 395 people
- Sponsor
- Bial - Portela C S.A.
Partial Epilepsy
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)
- Trial name
- NCT00908349
- Testing
- Oxcarbazepine XR
- Where
- 58 sites in United States, Bulgaria and 6 more
- Volunteers
- 214 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy, Epilepsies, Partial
An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy
The purpose of this study is to evaluate the safety and preliminary effectiveness of the novel compound RWJ-333369 in patients with partial onset seizures who are currently being treated with 1 or 2 concomitant antiepileptic…
- Trial name
- NCT00210652
- Testing
- RWJ 333369:
- Volunteers
- 47 people
- Sponsor
- SK Life Science, Inc.
Focal Epilepsy
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
- Trial name
- RISE 3 (NCT06309966)
- Testing
- BHV-7000
- Where
- 150 sites in United States, Australia and 14 more
- Volunteers
- 390 people
- Sponsor
- Biohaven Therapeutics Ltd.
Epilepsy, Partial Seizure
RNS System RESPONSE Study
To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
- Conditions
- Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy
- Trial name
- RESPONSE (NCT04839601)
- Testing
- RNS System
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- NeuroPace
Focal Epilepsy
Long-term Safety and Tolerability of BHV-7000
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
- Trial name
- NCT06443463
- Testing
- BHV-7000
- Where
- 283 sites in United States, Argentina and 25 more
- Volunteers
- 660 people
- Sponsor
- Biohaven Therapeutics Ltd.
Epilepsy, Seizures
EpiCare@Home Validation Study for Focal Onset Seizures
The goal of this clinical trial is to validate a wearable seizure monitoring device, EpiCare@Home, as an objective seizure monitoring tool for people with focal onset epileptic seizures.
- Conditions
- Epilepsy, Seizures, Seizures, Focal, Seizure, Refractory
- Trial name
- NCT05738226
- Testing
- EpiCare@Home, wearable multimodal seizure monitoring system
- Where
- United States
- Sponsor
- Byteflies
Epilepsy, Partial Seizures
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
The purpose of this study is to determine whether levetiracetam as adjunctive therapy is effective in the treatment of partial seizures, with or without secondary generalization, associated with refractory focal epilepsy.
- Trial name
- Mozart (NCT01392768)
- Testing
- Levetiracetam
- Volunteers
- 126 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.